Trulieve Retires Florida Cultivation Mortgage Ahead of Schedule

TALLAHASSEE – Trulieve Cannabis Corp. announced the full early repayment of mortgage notes secured by a cultivation facility in Jefferson County, Florida, bringing total outstanding debt down to approximately $225 million, according to the company’s press release.

The approximately $65 million mortgage was retired before its scheduled maturity date, funded through operating cash flow. Trulieve generated $109 million in cash from operations during H1 2026, closing its second quarter with $325 million in cash and $289 million in outstanding debt at a blended interest rate of 9.6%.

CEO Kim Rivers framed the early repayment as a deliberate long-term decision:

“We used our strong cash generation to repay this mortgage prior to its maturity date as part of our long-term strategy to bolster our financial position,” she said. “Reducing balance sheet leverage lowers our annual interest expense, improving profitability and cash flow. Given the strength of our platform, we are well positioned to fund growth initiatives in the near term including expansion in Georgia and Texas, pending regulatory approvals.”

The announcement comes roughly four months after Trulieve became the first U.S. Cannabis company listed on the New York Stock Exchange, following a corporate restructuring that separated its Harvest Health operations.

Georgia and Texas anchor Trulieve’s near-term expansion priorities. Georgia’s medical Cannabis program was significantly broadened on July 1, and the company reported that traffic at its dispensaries in the state tripled during the program’s first two weeks, though inventory constraints eventually slowed momentum. Trulieve currently operates six dispensaries in Georgia and expects to open a seventh location in Dunwoody before year-end. In Texas, the company has production capacity ready for inspection across all eleven public health regions and is awaiting final licensure under the state’s Compassionate Use Program.

With reduced debt service costs and a lighter tax obligation on its core medical operations, Trulieve now has greater discretion over how it deploys cash. The company has also announced a share repurchase program worth up to $50 million and is targeting at least $225 million in full-year operating cash flow.

For those tracking the financial maturation of the U.S. Cannabis sector, this transaction reflects something broader than balance sheet housekeeping. Trulieve is systematically reducing fixed costs, expanding into new state markets with strong demand signals, and benefiting from the first meaningful federal regulatory relief the industry has seen in decades. When these forces reinforce each other [and right now they are] the financial leverage shifts firmly in the company’s direction.